Protein-protein interactions as antibiotic targets: A medicinal chemistry perspective
- PMID: 30004586
- DOI: 10.1002/med.21519
Protein-protein interactions as antibiotic targets: A medicinal chemistry perspective
Abstract
There are 27 small molecule protein-protein interaction (PPI) modulators in Phase I, II, and III clinical trials targeting cancer, viruses, autoimmune disorders, and as immune suppression agents. Targeting PPIs as an antibiotic drug discovery strategy remains in relative infancy by comparison. However, a number of molecules are in development which target PPI within the replisome, divisome, transcriptome, and translatome are showing significant promise at the medicinal chemistry stage of drug development. Hence, the success of future PPI agents as antibiotics will build upon the techniques and design strategies of these molecules.
Keywords: antibacterial; antibiotic; protein-protein interaction (PPI).
© 2018 Wiley Periodicals, Inc.
References
REFERENCES
-
- Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161-168.
-
- Shore CK, Coukell A. Roadmap for antibiotic discovery. Nat Microbiol. 2016;1:16083.
-
- Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013....
-
- Wright GD. Molecular mechanisms of antibiotic resistance. Chem Commun. 2011;47:4055.
-
- Mullard A. Preclinical antibiotic pipeline gets a pick-me-up. Nat Rev Drug Discov. 2017;16:741-742.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical